Companies › ImmVirx
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IVX037 Oncolytic RNA virus | – | Phase 1 | Colorectal Cancer | Jun 2028 |
| Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 1 | Colorectal Cancer | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05427487 | IVX037 | Phase 1 | Colorectal Cancer | Oncology | Jun 2028 |
| NCT05427487 | Sintilimab | Phase 1 | Colorectal Cancer | Oncology | Jun 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.